The Cigna Group

NYSE:CI 주식 리포트

시가총액: US$77.1b

Cigna Group 향후 성장

Future 기준 점검 1/6

Cigna Group (는) 각각 연간 6.7% 및 4.1% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 10.6% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 18% 로 예상됩니다.

핵심 정보

6.7%

이익 성장률

10.64%

EPS 성장률

Healthcare 이익 성장18.3%
매출 성장률4.1%
향후 자기자본이익률18.03%
애널리스트 커버리지

Good

마지막 업데이트20 May 2026

최근 향후 성장 업데이트

분석 기사 • May 04

The The Cigna Group (NYSE:CI) First-Quarter Results Are Out And Analysts Have Published New Forecasts

The Cigna Group ( NYSE:CI ) came out with its first-quarter results last week, and we wanted to see how the business is...

Recent updates

Seeking Alpha • May 18

Cigna: Shares Marching To Full Recovery

Summary Cigna Group is reiterated as a "Buy," driven by strong Q1 2026 results, raised guidance, and sustained business momentum. CI’s pharmacy and behavioral health segments are fueling revenue growth, while divestitures and PBM reform temporarily temper 2026 earnings. Shares trade at a 25% discount to a $377 fair value estimate, offering potential 15% annual total returns through 2031. Cigna’s robust balance sheet, market-leading dividend coverage, and growth catalysts in biosimilars and behavioral health underpin the investment thesis. Read the full article on Seeking Alpha
분석 기사 • May 04

The The Cigna Group (NYSE:CI) First-Quarter Results Are Out And Analysts Have Published New Forecasts

The Cigna Group ( NYSE:CI ) came out with its first-quarter results last week, and we wanted to see how the business is...
내러티브 업데이트 • May 02

CI: Leadership Transition And Buybacks Will Support Future Share Upside

Analysts have increased their price target on Cigna Group by about $1. This reflects small adjustments to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions in their models.
내러티브 업데이트 • Apr 17

CI: Leadership Transition And Buybacks Will Drive Future Upside

Analysts have trimmed their average price target on Cigna Group by about $0.38 to roughly $338.42, reflecting small updates to fair value estimates, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News The Cigna Group plans a leadership transition, with current CEO David M.
내러티브 업데이트 • Apr 02

CI: Leadership Transition And Onsite Care Expansion Will Drive Future Upside

Analysts have slightly refined their view on Cigna Group, trimming the price target by a fraction to $338.79 as updated assumptions for revenue growth, profit margins, and future P/E bring the model into closer alignment with their latest expectations. What's in the News Cigna Group plans a leadership transition, with David M.
내러티브 업데이트 • Mar 19

CI: Onsite Care Expansion And Leadership Transition Will Support Future Upside

Analysts have nudged their fair value estimate for Cigna Group from about $336.67 to roughly $338.80. This reflects updated views on revenue growth, profit margins, and an anticipated forward P/E of around 13.43x.
내러티브 업데이트 • Mar 05

CI: Onsite Care Expansion Will Support Future Upside Potential

Analysts now set Cigna Group's fair value estimate at about $336.67, up from roughly $332.62, reflecting updated assumptions that incorporate slightly higher revenue growth, profit margins, and a lower future P/E multiple. What's in the News Cigna Group plans a leadership transition, with CEO David M.
내러티브 업데이트 • Feb 19

CI: Higher Margin Outlook And Onsite Care Expansion Will Support Upside

Analysts have modestly lifted their price target on Cigna Group to $332.62 from $326.92, citing updated assumptions that combine slightly lower revenue growth with a higher profit margin and a future P/E of 15.62. What's in the News A class action lawsuit has been filed against Express Scripts, Cigna, and Evernorth, alleging a rebate diversion scheme that used an offshore entity, Ascent, to collect billions of dollars in kickbacks labeled as fees instead of passing rebates through to pharmacy benefit management clients, including the Plumbers' Welfare Fund.
내러티브 업데이트 • Feb 04

CI: Onsite Clinic And Stable Assumptions Will Support Future Upside

Analysts have kept their price target for The Cigna Group broadly unchanged at about US$327, citing only slight adjustments to revenue growth, profit margin and future P/E assumptions rather than any major shift in their outlook. What's in the News Hankook Tire America Corp.
내러티브 업데이트 • Jan 21

CI: Completed Buybacks And New Employee Clinic Will Support Future Upside

Analysts have nudged their fair value estimate for Cigna Group slightly higher to US$326.92 from US$325.57, citing minor refinements to discount rate assumptions, revenue growth expectations, profit margin inputs, and the forward P/E multiple used in their models. What's in the News Hankook Tire America Corp.
내러티브 업데이트 • Jan 07

CI: Massive Share Buyback And Clinic Expansion Will Support Future Earnings Upside

Analysts have slightly reduced their price target for Cigna Group, trimming fair value by about $0.69 to $325.57 as they factor in a more moderate revenue growth outlook, along with a small improvement in expected profit margins and future P/E assumptions. What's in the News Hankook Tire America Corp.
내러티브 업데이트 • Dec 15

CI: Massive Share Buyback Will Drive Future Earnings Upside Momentum

Narrative Update on Cigna Group Analysts have slightly lowered their price target on Cigna Group by approximately $2 to around $326 per share, reflecting modest tweaks to assumptions on long term growth, profitability, and valuation multiples, while maintaining a broadly constructive outlook. What's in the News Cigna Group reported that between July 1 and September 30, 2025, it repurchased no additional shares under its existing authorization, having already completed the buyback of about 133.5 million shares, or 41.09% of shares outstanding, for roughly $34.44 billion since the program was announced in December 2018 (company filing).
내러티브 업데이트 • Nov 30

CI: Massive Share Buyback Will Drive Future Earnings Upside Momentum

Analysts have raised their price target for Cigna Group to $328.35 per share, citing moderate adjustments to key financial metrics. These include a higher projected future price-to-earnings ratio and continued expectations for growth and profitability.
내러티브 업데이트 • Nov 16

CI: Significant Buybacks And 2026 Guidance Will Drive Upside Momentum

Narrative Update on Cigna Group Analysts have lowered their price target for Cigna Group from $349.04 to $328.35. This change reflects adjustments for a slightly higher discount rate as well as revised expectations for revenue growth and profit margins.
내러티브 업데이트 • Nov 01

CI: Share Repurchase Momentum Will Drive Long-Term Shareholder Value Creation

Analysts have lowered their price target for Cigna Group from $369.13 to $349.04. This change reflects updated expectations around modestly higher revenue growth, which are offset by a slight dip in profit margin projections.
분석 기사 • Jul 10

The Cigna Group (NYSE:CI) Screens Well But There Might Be A Catch

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 19x, you may...
분석 기사 • Jun 19

These 4 Measures Indicate That Cigna Group (NYSE:CI) Is Using Debt Reasonably Well

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Mar 31

The Cigna Group: Compelling Exposure To Diversified Healthcare At A Discount Price

Summary Cigna is positioned to benefit from utilization normalization and aims for 10%-14% annual EPS growth by reducing Medicare exposure and improving Commercial business. Despite industry challenges, Cigna achieved 8%-9% YoY EPS growth in 2023-2024, demonstrating strong cost discipline and effective management. The sale of Cigna's Medicare unit and focus on lower-cost biosimilars and streamlined care accessibility are key strategic moves for future growth. With an attractive valuation and minimal downside risk, Cigna stock is rated a BUY, offering at least 33% upside potential even in bearish conditions. Read the full article on Seeking Alpha
Seeking Alpha • Feb 17

Cigna Is A Buy: Market Overreaction Creates A Big Opportunity

Summary Cigna looks undervalued at under 10x earnings, with strong growth potential. Evernorth continues to expand, adding to the company’s long-term value. Large stock buybacks are supporting earnings per share and investor returns. Regulatory risks, rising costs, and competition remain challenges to watch. If Cigna meets its targets, the stock could rise 20-30% from here. Read the full article on Seeking Alpha
Seeking Alpha • Jan 18

Cigna: Buy The Drop On This Undervalued Growth Stock

Summary Cigna's current valuation presents a compelling opportunity, trading at a forward PE of 9.9, significantly below its historical average of 12.0x. The company carries diversified revenue streams and consistent earnings growth, with Healthcare and Evernorth divisions driving strong performance and a 13% EPS CAGR over 10 years. Management targets 10-14% long-term annual EPS growth, supported by increased biosimilar adoption, behavioral health services growth, and aggressive share buybacks. CI's growing dividend and robust fundamentals make it an attractive choice for value and growth investors, despite potential regulatory and macroeconomic risks. Read the full article on Seeking Alpha
Seeking Alpha • Dec 13

Cigna And The Risk Of PBMs - I'm Staying Out Above $230/Share

Summary Cigna faces significant risks due to potential healthcare reforms and scrutiny on PBMs, making it a "Hold" until it drops below $230/share. The US healthcare system's high costs and structural issues contribute to the uncertainty surrounding Cigna's long-term profitability and business model. Despite strong historical performance, the potential breakup of PBMs and legislative changes could drastically impact Cigna's future earnings and growth. The current valuation does not justify investment; Cigna's appeal lies in its fundamental strengths but is overshadowed by systemic risks and political uncertainties. Read the full article on Seeking Alpha
Seeking Alpha • Sep 26

Cigna: This Dividend Grower Could Be Worth Buying Now

Summary The managed care company's total revenue and non-GAAP EPS climbed higher in the second quarter. Cigna's dividend is comfortably covered by non-GAAP EPS and free cash flow. Shares of the stock appear to be priced at a 17% discount to fair value. Cigna could be set up to generate strong total returns in the next couple of years. Read the full article on Seeking Alpha
Seeking Alpha • Sep 19

Cigna: Growth From Specialty Pharmacy And Care; Initiate With 'Buy'

Summary I am initiating a 'Buy' rating for Cigna with a one-year target price of $450 per share, driven by strong Specialty and Cigna Healthcare growth. Cigna's Specialty Pharmacy and Care Market, accounting for 30% of revenue, is poised for above-market growth due to its leadership in the chronic market and biosimilar offerings. Cigna Healthcare's divestiture of low-margin Medicare businesses will allow focus on employer-sponsored plans, targeting small and mid-size enterprises, contributing to 7% organic revenue growth. Despite low operating margins and elevated cost trends, Cigna's share repurchase program and SG&A optimization are expected to support future margin expansion and free cash flow growth. Read the full article on Seeking Alpha
Seeking Alpha • Jul 29

Cigna Group: Services Focus Leads To Outperformance

Summary Cigna Group's medical memberships are focused on "services-only" commercial memberships. The fee-based rather than risk-based nature of these memberships makes Cigna more resilient to rising medical costs. The Evernorth segment should see high-single-digit growth for the foreseeable future, driven by Healthcare Services and specialty pharmacy Accredo. The low valuation coupled with the mid-single-digit earnings growth outlook makes Cigna stock attractive at current prices. Read the full article on Seeking Alpha
Seeking Alpha • Jul 12

Cigna: Game Over For PBMs?

Summary Pharmacy Benefit Managers are increasingly in the spotlight of regulators and the media, potentially leading to government intervention. Express Scripts, Cigna's PBM, is responsible for nearly 75% of the company's revenue, which raises the question of whether CI stock is still a safe investment. This article discusses the potential implications in a scenario-based approach, focusing on segment profit, consolidated profit, dividend safety, and valuation. In addition, I share my thoughts on the recent opioid litigation in Arkansas and explain why I continue to sleep well with my investment in Cigna. Read the full article on Seeking Alpha

이익 및 매출 성장 예측

NYSE:CI - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수
12/31/2028312,6067,88410,11711,2259
12/31/2027296,9607,72810,10810,39314
12/31/2026284,0046,6229,0399,39314
3/31/2026277,8926,2887,6608,812N/A
12/31/2025274,9005,9578,3899,601N/A
9/30/2025268,0776,1477,4378,664N/A
6/30/2025262,0235,0183,9445,292N/A
3/31/2025255,3685,0346,0107,443N/A
12/31/2024247,1213,4348,95710,363N/A
9/30/2024232,5863,0395,1846,618N/A
6/30/2024217,9403,7087,9609,398N/A
3/31/2024206,0033,62010,16011,625N/A
12/31/2023195,2655,16410,24011,813N/A
9/30/2023189,9045,32810,89212,445N/A
6/30/2023186,1376,67711,41412,902N/A
3/31/2023183,0296,77410,23911,654N/A
12/31/2022180,5186,7047,3618,656N/A
9/30/2022180,4536,6279,57810,832N/A
6/30/2022179,4605,4918,4029,668N/A
3/31/2022177,1135,4016,9288,128N/A
12/31/2021174,0695,3706,0377,191N/A
9/30/2021170,1028,3846,0417,210N/A
6/30/2021166,7698,1514,9155,986N/A
3/31/2021162,9038,4388,4879,556N/A
12/31/2020160,4018,4589,25610,350N/A
9/30/2020156,9345,3007,7648,849N/A
6/30/2020154,5355,2639,33910,415N/A
3/31/2020154,0894,9177,0578,180N/A
12/31/2019153,5665,104N/A9,485N/A
9/30/2019129,6214,271N/A6,818N/A
6/30/2019102,5223,692N/A4,981N/A
3/31/201975,1833,090N/A4,937N/A
12/31/201848,6502,637N/A3,770N/A
9/30/201844,7682,759N/A4,219N/A
6/30/201843,8002,547N/A4,830N/A
3/31/201842,7452,554N/A4,532N/A
12/31/201741,8062,237N/A4,086N/A
9/30/201741,3322,353N/A4,358N/A
6/30/201740,7232,249N/A5,035N/A
3/31/201740,2581,946N/A4,684N/A
12/31/201639,8381,867N/A4,026N/A
9/30/201639,2521,911N/A4,315N/A
6/30/201638,7612,002N/A3,017N/A
3/31/201638,2932,080N/A3,117N/A
12/31/201537,8762,094N/A2,933N/A
9/30/201537,2762,135N/A2,319N/A
6/30/201536,6442,122N/A2,175N/A

애널리스트 향후 성장 전망

수입 대 저축률: CI 의 연간 예상 수익 증가율(6.7%)이 saving rate(3.5%)보다 높습니다.

수익 vs 시장: CI 의 연간 수익(6.7%)이 US 시장(16.8%)보다 느리게 성장할 것으로 예상됩니다.

고성장 수익: CI 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: CI 의 수익(연간 4.1%)이 US 시장(연간 11.6%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: CI 의 수익(연간 4.1%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: CI의 자본 수익률은 3년 후 18%로 낮을 것으로 예상됩니다.

성장 기업 찾아보기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/20 19:38
종가2026/05/20 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

The Cigna Group는 40명의 분석가가 다루고 있습니다. 이 중 17명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
null nullArgus Research Company
Hua HaBaird
Andrew MokBarclays